Co-Diagnostics Reports Staggering $46.9M Net Loss, Going Concern Warning, and Significant Dilution Amidst Nasdaq Compliance Challenges
CODX is trading near its 52-week low of $1.66 (6.9% above the low) on light trading volume (0.2× avg).
Summary
Co-Diagnostics reported a $46.9 million net loss for 2025, an 84% revenue decline, and received a 'going concern' warning. The company undertook significant dilutive capital raises and a reverse stock split to maintain Nasdaq compliance, and announced a 26% workforce reduction.
Key Events · Financing and Capital Events · CODX
-
Staggering Net Loss and Revenue Decline
The company reported a net loss of $46.9 million for the fiscal year ended December 31, 2025, a significant increase from $37.6 million in 2024. Total revenue for 2025 plummeted by 84% to $0.6 million from $3.9 million in 2024.
-
Going Concern Warning Issued
Both the independent registered public accounting firm and management have expressed substantial doubt about the company's ability to continue as a going concern, citing recurring losses from operations and negative operating cash flows.
-
Massive Impairment Charge
Co-Diagnostics recognized an $18.9 million impairment charge related to in-process research and development intangible assets, primarily due to a significant decline in stock price and market capitalization.
-
Significant Dilutive Capital Raises
The company completed two registered direct offerings in Q4 2025, raising approximately $10.8 million in gross proceeds. Additionally, it sold 31,667 shares under a new $10.0 million at-the-market (ATM) program by year-end, with further sales of 1,507,434 shares for $4.3 million in net proceeds occurring after December 31, 2025.
Analysis · CODX · Industrial Applications And Services
Co-Diagnostics' annual report reveals a company in severe financial distress, marked by a substantial net loss and an explicit 'going concern' warning from both management and auditors. The company's revenue has plummeted, and it incurred a massive impairment charge, highlighting operational challenges. While recent dilutive capital raises and a reverse stock split have temporarily addressed liquidity and Nasdaq listing requirements, the underlying financial performance and the ongoing legal risks present a highly challenging outlook. The subsequent workforce reduction underscores the need for drastic cost-cutting measures.
At the time of this filing, CODX was trading at $1.77 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.66 to $46.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.